Merck MRK and AbbVie ABBV are leading pharmaceutical companies with strong portfolios in oncology and immunology. While ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

Merck already has the world’s biggest selling oral treatment for type 2 diabetes, its DPP-4-based drugs Januvia and Janumet, but it is playing catch-up in the SGLT2 market. The monotherapy and ...

Wegovy and Zepbound are just the latest drug dyads to face-off in the competitive pharma market, continuing a legacy of ...

Merck, known as Merck, Sharp and Dohme (MSD) outside the US, markets several diabetes drugs, such as Januvia (sitagliptin), and the recently-approved Steglatro (ertugliflozin) as part of a ...

Three Motley Fool contributors think they've identified magnificent stocks that could double or more by 2030. Here's why they ...

The Heart Failure Drugs Market is poised for a transformative decade between 2025 and 2035. As heart failure continues to ...

Liver fibrosis is the build up of scar tissue in the liver when it tries to heal itself. Symptoms may include fatigue, ...

Novo Nordisk NVO and Eli Lilly LLY dominate the diabetes and obesity market on the back of the tremendous success of their ...

Investing isn’t easy, and given the current market volatility, retail investors are on edge, worrying about their portfolios.

In people with HIV taking antiretroviral therapy, excessive visceral abdominal fat drives cardiovascular disease risk, even ...

Mark Esser, an executive at Big Pharma firm AstraZeneca, has been named the inaugural leader of UVa's future Manning ...